Lunai Bioworks (LNAI) EBT Margin (2013 - 2026)

Lunai Bioworks (LNAI) posted quarterly EBT Margin of 7570.01% for Q1 2026, up 97.75% quarter-over-quarter from 336295.49% in Q2 2016.

Lunai Bioworks (LNAI) EBT Margin (2013 - 2026) Analysis & Trends

Lunai Bioworks' EBT Margin history runs 3 years deep, the most recent figure standing at 7570.01% for Q1 2026.

In Q1 2026, EBT Margin changed N/A year-over-year to 7570.01%; the TTM figure through Mar 2026 stood at 156483.9% (changed N/A YoY), while the FY2016 annual figure was 5139.3%, changed N/A from the prior year.
EBT Margin for Q1 2026 stood at 7570.01%, up from 336295.49% in the prior quarter.
The five-year high for EBT Margin was 7570.01% in Q1 2026, with the low at 7570.01% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00	-7,570.01%

Download Data